Journal
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 189, Issue 1, Pages 12-20Publisher
WILEY
DOI: 10.1111/cei.12966
Keywords
interleukin 6; rheumatoid arthritis; T cell plasticity; Th17/T-reg balance; tocilizumab
Categories
Funding
- FONDECYT [1121100, 11121497]
Ask authors/readers for more resources
Therapeutic blockage of cytokine signalling in autoimmune diseases has improved our understanding of the role of these cytokines in triggering, shaping and perpetuating autoimmune responses. In rheumatoid arthritis (RA), immunopathology is driven by a predominance of arthritogenic T helper cells secreting interferon- [T helper type 1 (Th1)] and interleukin (IL)-17 (Th17) over regulatory T cells (T-reg). The pleiotropic cytokine IL-6 is crucial to the differentiation of Th17 cells and the balance between pathogenic Th17 and protective T-reg. Targeting the IL-6 receptor (IL-6R) by humanized antibodies improves signs and symptoms of RA, and has provided new insights into the mechanisms of inflammation and immune regulation. Here we review current evidence on the role of IL-6 in the pathogenesis of RA and the molecular consequences of IL-6R blockage in disease, with special focus on the Th17/T-reg balance and plasticity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available